OBJECTIVES: The purpose of the study was to evaluate the effect of long-term β(1)-aderergic receptor (AR) blockade on left ventricular (LV) remodeling and function in patients with chronic, isolated, degenerative mitral regurgitation (MR). BACKGROUND: Isolated MR currently has no proven therapy that attenuates LV remodeling or preserves systolic function. METHODS:Thirty-eight asymptomatic subjects with moderate to severe, isolated MR were randomized either to placebo or β(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years. Magnetic resonance imaging with tissue tagging and 3-dimensional analysis was performed at baseline and at 6-month intervals for 2 years. Rate of progression analysis was performed for endpoint variables for primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastolic (ED) mass/ED volume ratio, LV ED 3-dimensional radius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV early diastolic filling rate. RESULTS: Baseline LV magnetic resonance imaging or demographic variables did not differ between the 2 groups. Significant treatment effects were found on LV ejection fraction (p = 0.006) and LV early diastolic filling rate (p = 0.001), which decreased over time in untreated patients on an intention-to-treat analysis and remained significant after sensitivity analysis. There were no significant treatment effects found on LV ED or LV end-systolic volumes, LV ED mass/LV ED volume or LV ED 3-dimensional radius/wall thickness, or LV longitudinal strain rate. Over 2 years, 6 patients treated in the placebo group and 2 patients in the β(1)-AR blockade group required mitral valve surgery (p = 0.23). CONCLUSIONS:β(1)-AR blockade improves LV function over a 2-year follow-up in isolated MR and provides the impetus for a large-scale clinical trial with clinical outcomes. (Molecular Mechanisms of Volume Overload-Aim 1 [SCCOR in Cardiac Dysfunction and Disease]; NCT01052428).
RCT Entities:
OBJECTIVES: The purpose of the study was to evaluate the effect of long-term β(1)-aderergic receptor (AR) blockade on left ventricular (LV) remodeling and function in patients with chronic, isolated, degenerative mitral regurgitation (MR). BACKGROUND: Isolated MR currently has no proven therapy that attenuates LV remodeling or preserves systolic function. METHODS: Thirty-eight asymptomatic subjects with moderate to severe, isolated MR were randomized either to placebo or β(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years. Magnetic resonance imaging with tissue tagging and 3-dimensional analysis was performed at baseline and at 6-month intervals for 2 years. Rate of progression analysis was performed for endpoint variables for primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastolic (ED) mass/ED volume ratio, LV ED 3-dimensional radius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV early diastolic filling rate. RESULTS: Baseline LV magnetic resonance imaging or demographic variables did not differ between the 2 groups. Significant treatment effects were found on LV ejection fraction (p = 0.006) and LV early diastolic filling rate (p = 0.001), which decreased over time in untreated patients on an intention-to-treat analysis and remained significant after sensitivity analysis. There were no significant treatment effects found on LV ED or LV end-systolic volumes, LV ED mass/LV ED volume or LV ED 3-dimensional radius/wall thickness, or LV longitudinal strain rate. Over 2 years, 6 patients treated in the placebo group and 2 patients in the β(1)-AR blockade group required mitral valve surgery (p = 0.23). CONCLUSIONS: β(1)-AR blockade improves LV function over a 2-year follow-up in isolated MR and provides the impetus for a large-scale clinical trial with clinical outcomes. (Molecular Mechanisms of Volume Overload-Aim 1 [SCCOR in Cardiac Dysfunction and Disease]; NCT01052428).
Authors: L J Dell'italia; E Balcells; Q C Meng; X Su; D Schultz; S P Bishop; N Machida; I M Straeter-Knowlen; G H Hankes; R Dillon; R E Cartee; S Oparil Journal: Am J Physiol Date: 1997-08
Authors: Mustafa I Ahmed; James D Gladden; Silvio H Litovsky; Steven G Lloyd; Himanshu Gupta; Seidu Inusah; Thomas Denney; Pamela Powell; David C McGiffin; Louis J Dell'Italia Journal: J Am Coll Cardiol Date: 2010-02-16 Impact factor: 24.094
Authors: H Tsutsui; F G Spinale; M Nagatsu; P G Schmid; K Ishihara; G DeFreyte; G Cooper; B A Carabello Journal: J Clin Invest Date: 1994-06 Impact factor: 14.808
Authors: Rajendra H Mehta; Mark A Supiano; Hakan Oral; P Michael Grossman; Daniel S Montgomery; Marla J Smith; Mark R Starling Journal: Am Heart J Date: 2003-06 Impact factor: 4.749
Authors: Brandon George; Thomas Denney; Himanshu Gupta; Louis Dell'Italia; Inmaculada Aban Journal: Ann Appl Stat Date: 2016-03-25 Impact factor: 2.083
Authors: Junying Zheng; Danielle M Yancey; Mustafa I Ahmed; Chih-Chang Wei; Pamela C Powell; Mayilvahanan Shanmugam; Himanshu Gupta; Steven G Lloyd; David C McGiffin; Chun G Schiros; Thomas S Denney; Gopal J Babu; Louis J Dell'Italia Journal: Circ Heart Fail Date: 2013-12-02 Impact factor: 8.790
Authors: Mustafa I Ahmed; Jason L Guichard; Rajasekaran Namakkal Soorappan; Shama Ahmad; Nithya Mariappan; Silvio Litovsky; Himanshu Gupta; Steven G Lloyd; Thomas S Denney; Pamela Cox Powell; Inmaculada Aban; James Collawn; James E Davies; David C McGiffin; Louis J Dell'Italia Journal: J Thorac Cardiovasc Surg Date: 2016-06-25 Impact factor: 5.209
Authors: Chun G Schiros; Mustafa I Ahmed; Thriveni Sanagala; Wei Zha; David C McGiffin; Marcas M Bamman; Himanshu Gupta; Steven G Lloyd; Thomas S Denney; Louis J Dell'Italia Journal: Am J Cardiol Date: 2013-01-17 Impact factor: 2.778